Clinical Trial Update: A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B [Phase 2]

View source ↗

Summary

This document updates a Phase II clinical study evaluating BW-20507 in combination with PEG-IFNα for chronic hepatitis B, with the trial currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• BW-20507
• PEG-IFNα (pegylated interferon alfa)

Snippet

Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. | Conditions: Chronic Hepatitis B | Phase 2 | Status: ACTIVE_NOT_RECRUITING